Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8967176 | 0.98 | HRH3 (0.58) | HRH3MEN1KMT2AL3MBTL1ATM | |
| SCHEMBL10100371 | 0.98 | HRH3 (0.50) | HRH3MEN1KMT2AL3MBTL1ATM | |
| SCHEMBL9917380 | 0.94 | HRH3 (0.50) | HRH3MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL8967124 | 0.94 | HRH3 (0.50) | HRH3MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL9917280 | 0.92 | MEN1 (0.50) | HRH3MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL22509507 | 0.88 | MEN1 (0.46) | HRH3MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL20328700 | 0.87 | HRH3 (0.44) | HRH3MEN1KMT2AKDM4E | |
| SCHEMBL20328709 | 0.87 | HRH3 (0.47) | HRH3MEN1KMT2A | |
| SCHEMBL1698707 | 0.85 | PSMB1 (0.47) | HRH3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL9917381 | 0.85 | PSMB1 (0.47) | HRH3MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10420759-B2 | Small molecule therapies for pulmonary hypertension | CREIGHTON UNIVERSITY (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190038551-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20170290819-A1 | SMALL MOLECULE THERAPIES FOR PULMONARY HYPERTENSION | CREIGHTON UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| US-20170290819-A1 | SMALL MOLECULE THERAPIES FOR PULMONARY HYPERTENSION | CREIGHTON UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20110008284-A1 | NOVEL CLYCLOSPORIN ANALOGUES | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-7771742-B2 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer; pharmacokinetics | ALLERGAN, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080260803-A1 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer | ALLERGAN,INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | ALLERGAN,INC (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-0468434-B1 | Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis | MERRELL DOW PHARMA (US) | 1996-02-28 | — | — | EP | disclosed |
| US-5348964-A | Anticholesterol agents or fungicides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-20 | — | — | US | disclosed |
| CN-1058399-A | New piperidine ether and thioether as cholesteral biosynthesis inhibitor | MERRELL DOW PHARMA (US) | 1992-02-05 | — | — | CN | disclosed |
| EP-0468434-A1 | Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis | MERRELL PHARMACEUTICALS INC. (US) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008284-A1 | NOVEL CLYCLOSPORIN ANALOGUES | CHP1, FKBP1B, FKBP1A | HRH3 3071/4885MEN1 2837/4885KMT2A 4153/4885 |
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | HRH3 3363/4885MEN1 1893/4885KMT2A 3291/4885 |
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | HRH3 2517/4885MEN1 3077/4885KMT2A 1212/4885 |
| US-20170290819-A1 | SMALL MOLECULE THERAPIES FOR PULMONARY HYPERTENSION | PTGIR, VASP, MYLK | HRH3 1009/4885MEN1 3697/4885KMT2A 1456/4885 |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | KDR, PTK2B, DSTYK | HRH3 2517/4885MEN1 3077/4885KMT2A 1212/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | HRH3 3604/4885MEN1 595/4885KMT2A 2784/4885 |
| US-10420759-B2 | Small molecule therapies for pulmonary hypertension | PTGIR, VASP, MYLK | HRH3 1009/4885MEN1 3697/4885KMT2A 1456/4885 |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | HRH3 2521/4885MEN1 3082/4885KMT2A 1226/4885 |
| US-20190038551-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | HRH3 2521/4885MEN1 3082/4885KMT2A 1226/4885 |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | VEGFA, PTK2, KDR | HRH3 3764/4885MEN1 1851/4885KMT2A 1220/4885 |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | FLT1, JAK1, KDR | HRH3 4038/4885MEN1 4086/4885KMT2A 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.